dostarlimab news

All news on dostarlimab (also known as Jemperli): plants, production capacities, investments and involved companies.

24 August 2026

GSK’s Jemperli accepted for priority FDA review in dMMR/MSI‑H locally advanced rectal cancer

FDA sets PDUFA Feb 2027 for Jemperli’s supplemental filing based on AZUR‑1 data showing sustained 12‑month complete responses, potentially avoiding chemo, radiation and surgery.
28 July 2026

GSK Q2: strong core results, R&D acceleration and 20+ Phase III starts in 2026

Core operating profit +7% and core EPS +9%; sales up, driven by Specialty Medicines and Vaccines; new R&D centre and a 3-year £1.9bn annual savings target to fund late-stage pipeline.
13 July 2026

GSK’s Jemperli shows sustained clinical complete responses in dMMR/MSI‑H locally advanced rectal cancer

Interim phase II results met primary endpoint (cCR12); trial suggests some patients may avoid chemo, radiation and surgery. Data to be shared with regulators including for US accelerated review.

Who will be producing dostarlimab in the future?

Find out with chemXplore Alpha

Learn more